Evaluation of Adropin Levels in Cardiovascular Disease

https://doi.org/10.55529/jpdmhd.41.22.30

Authors

  • Mutlak M. Taha Department of Biology, College of Science, Tikrit University, Tikrit, Iraq.
  • Saria N. Muhsen Department of Biology, College of Science, Tikrit University, Tikrit, Iraq.

Keywords:

Myocardial Infarction, Angina Pectoris, Adropin Biomarker.

Abstract

Biomarker studies for the diagnosis of myocardial infarction are continuing. Adropin is a biomarker that has been researched and found to have various effects. The purpose of this study was to look at the adropin levels of patients who had a myocardial infarction and angina pectoris.

Material and Methods: The control group comprised 30 individuals whose troponin levels did not rise and no coronary lesions were found. In the myocardial infarction group, 30 patients had an elevated ECG, and 30 patients had angina pectoris. They were diagnosed by clinicians and tested for Adropin, Fetuin-A, Selenoprotein-P, MDA, and Copeptin.

Results: In the MI group, a significant increase was observed in the adropin level p < 0.01**. While a strong positive correlation existed between Fetuin-A and adropin (r= 0.82, p< 0.001) as well as between selenoprotein-P and adropin (r= 0.64, p< 0.001).

Published

2024-01-31

How to Cite

Taha, M. M. ., & Muhsen, S. N. . (2024). Evaluation of Adropin Levels in Cardiovascular Disease. Journal of Prevention, Diagnosis and Management of Human Diseases , 4(01), 22–30. https://doi.org/10.55529/jpdmhd.41.22.30